Earnings call transcript: ResMed surpasses Q2 FY2025 expectations, stock dips
ResMed Inc . (NYSE:RMD) reported its financial results for the second quarter of fiscal year 2025, exceeding analysts' expectations with an earnings per share (EPS) of $2.43, surpassing the forecasted ...
HME News23h
ResMed moves to address ‘educational gap’ on PAP devices, GLP-1s
In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...